Association studies of Fcγ receptor polymorphisms with outcome in HER2+ breast cancer patients treated with trastuzumab in NCCTG (Alliance) Trial N9831

Cancer immunology research

Volumn 2, Issue 10, 2014, Pages 962-969

  Norton, Nadine ^a   Olson, Rebecca M ^a   Pegram, Mark ^a   Tenner, Kathleen ^a   Ballman, Karla V ^a   Clynes, Raphael ^a   Knutson, Keith L ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN; FC RECEPTOR; FCGR2B PROTEIN, HUMAN; MONOCLONAL ANTIBODY; TRASTUZUMAB; TUMOR PROTEIN;

ADULT; BREAST NEOPLASMS; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETICS; GENOTYPE; HUMAN; METABOLISM; MIDDLE AGED; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MIDDLE AGED; NEOPLASM PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ERBB-2; RECEPTORS, IGG; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84937512035     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0059     Document Type: Article

References (0)